Results suggest that women with RRMS can continue with a disease-modifying treatment while breastfeeding.
The study “Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions” was published in the journal Neurology: Neuroimmunology & Neuroinflammation.
The therapy is a monoclonal antibody that works by targeting the CD20 protein found on the surface of immune cells called B-cells, which are known to contribute to myelin damage, the hallmark of MS (myelin is the protective coat of nerve cells that is damaged in MS). Rituximab is used off-label with MS patients, meaning it is not approved as a therapy for this disease.
MS affects women mostly in their fertile years, but few studies have addressed the safety of taking MS therapies, like rituximab, during breastfeeding.
This lack of information forces “many women to choose between treating their neurologic disease or breastfeeding their infant, despite the many benefits of breastfeeding,” the researchers wrote.
Antibodies are large and not expected to pass to breast milk, but scientific proof is lacking.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?